Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

It is not known whether Omvoh (mirikizumab-mrkz) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy may ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out ...

Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active Crohn’s disease patients. The VIVID-2 trial has been evaluating continuous ...

If you continue to have this issue please contact [email protected]. More than 80% of Omvoh responders from the VIVID-1 study maintained endoscopic response at week 104 in VIVID-2.

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

These new medicines include Alzheimer's disease treatment Kisunla, ulcerative colitis medication Omvoh, and cancer drug Jaypirca. Of course, Lilly's most important new products are diabetes ...

Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available ...

showing that most patients with moderately to severely active Crohn’s disease achieved long-term clinical and endoscopic improvements after two years of continuous treatment with Omvoh.